Coya Therapeutics' Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer's patients, with no serious adverse events.

The results of flow cytometry showed that the levels of CCL2, IL-6 and TNF-αin macrophages in spinal cord, muscle, spleen and thymus of severely HFMD mice were significantly increased. The levels of ...